Anti-IL-17 phase II data for psoriasis: A review

Journal of Dermatological Treatment

Volumn 26, Issue 1, 2015, Pages 32-36

  Brown, Gabrielle ^a,b   Malakouti, Mona ^b,c   Wang, Eva ^b,d   Koo, John Y ^b   Levin, Ethan ^b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^d UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

Author keywords

Biologic medication; Brodalumab; Ixekizumab; Secukinumab

Indexed keywords

BRODALUMAB; IXEKIZUMAB; SECUKINUMAB; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; HEADACHE; HUMAN; INJECTION SITE REACTION; MAINTENANCE THERAPY; NEUTROPENIA; NEUTROPHIL; OPPORTUNISTIC INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; INTERLEUKIN-12; INTERLEUKIN-17; INTERLEUKIN-23; PSORIASIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84924331397     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2013.878448     Document Type: Article

References (32)

1. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin. 1996;14: 485-96. PubMed PMID: 8818558.
2. Arsiwala S. Infliximab: efficacy in psoriasis. Indian J Dermatol Venereol Leprol. 2013;79:S25-34. PubMed PMID: 23974692.
3. Novelli L, Chimenti MS, Chiricozzi A, Perricone R. The new era for the treatment of psoriasis and psoriatic arthritis: perspectives and validated strategies. Autoimmunity reviews. 2014 Jan;13(1):64-9. PubMed PMID: 24021172.
4. Mitra A, Fallen RS, Lima HC. Cytokine-based therapy in psoriasis. Clin Rev Allergy Immunol. 2013;44:173-82. PubMed PMID: 22426927.
5. Roark CL, Simonian PL, Fontenot AP, et al. Gammadelta T cells: an important source of IL-17. Curr Opin Immunol. 2008;20:353-7. PubMed PMID: 18439808. Pubmed Central PMCID: 2601685.
6. Chang SH, Dong C. A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses. Cell Res. 2007; 17:435-40. PubMed PMID: 17452998.
7. Qu N, Xu M, Mizoguchi I, et al. Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22, and IL-23, in inflammatory diseases. Clin Develop Immunol. 2013;2013:968549. PubMed PMID: 23956763. Pubmed Central PMCID: 3728507.
8. Pene J, Chevalier S, Preisser L, et al. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol. 2008;180:7423-30. PubMed PMID: 18490742.
9. Yilmaz SB, Cicek N, Coskun M, et al. Serum and tissue levels of IL-17 in different clinical subtypes of psoriasis. Arch Dermatol Res. 2012;304:465-9. PubMed PMID: 22426986.
10. Kagami S, Rizzo HL, Lee JJ, et al. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Investigat Dermatol. 2010;130: 1373-83. PubMed PMID: 20032993. PubMed Central PMCID: 2892169.
11. Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA dermatology. 2013 Oct;149(10):1180-5. PubMed PMID: 23945732.
12. Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2:52-72. PubMed PMID: 20926833.
13. Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Brit J Dermatol. 2013;168:412-21. PubMed PMID: 23106107.
14. Rich P, Sigurgeirsson B, Thaci D, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Brit J Dermatol. 2013;168:402-11. PubMed PMID: 23362969.
15. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. New Engl J Med. 2012;366:1190-9. PubMed PMID: 22455413.
16. Genovese MC, Van den Bosch F, Roberson SA, et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheumat 2010;62:929-39. PubMed PMID: 20131262.
17. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin- 17-receptor antibody for psoriasis. New Engl J Med. 2012;366:1181-9. PubMed PMID: 22455412.
18. Gaffen SL. Structure and signalling in the IL-17 receptor family. Nature Rev Immunol. 2009;9:556-67. PubMed PMID: 19575028. Pubmed Central PMCID: 2821718.
19. Wright JF, Bennett F, Li B, et al. The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex. J Immunol. 2008;181:2799-805. PubMed PMID: 18684971.
20. Wright JF, Guo Y, Quazi A, et al. Identification of an interleukin 17F/17A heterodimer in activated human CD4+ T cells. J Biol Chem. 2007;282:13447-55. PubMed PMID: 17355969.
21. Smith E, Stark MA, Zarbock A, et al. IL-17A inhibits the expansion of IL-17A-producing T cells in mice through "short-loop" inhibition via IL-17 receptor. J Immunol. 2008;181:1357-64. PubMed PMID: 18606690. PubMed Central PMCID: 2586908.
22. von Vietinghoff S, Ley K. IL-17A controls IL-17F production and maintains blood neutrophil counts in mice. J Immunol. 2009;183: 865-73. PubMed PMID: 19542376. Pubmed Central PMCID: 2759196.
23. Wu JJ, Poon KY, Channual JC, Shen AY. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012;148:1244-50. PubMed PMID: 22911151.
24. Puig L. Cardiovascular risk and psoriasis: the role of biologic therapy. [Riesgo cardiovascular y psoriasis: papel de la terapia biologica.] Actas Dermo-Sifiliograficas. 2012;103:853-62. PubMed PMID: 22591655.
25. de Boer OJ, van der Meer JJ, Teeling P, et al. Differential expression of interleukin-17 family cytokines in intact and complicated human atherosclerotic plaques. J Pathol. 2010;220:499-508. PubMed PMID: 20020510.
26. Csiszar A, Ungvari Z. Synergistic effects of vascular IL-17 and TNFalpha may promote coronary artery disease. Med-Hypotheses. 2004;63:696-8. PubMed PMID: 15325020.
27. Cheng X, Yu X, Ding YJ, et al. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin Immunol. 2008;127:89-97. PubMed PMID: 18294918.
28. Hashmi S, Zeng QT. Role of interleukin-17 and interleukin-17- induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. Coronary Artery Dis. 2006;17:699-706. PubMed PMID: 17119379.
29. Raychaudhuri SP, Raychaudhuri SK, Genovese MC. IL-17 receptor and its functional significance in psoriatic arthritis. Molec Cellular Biochem. 2012;359:419-29. PubMed PMID: 21894442.
30. Raychaudhuri SP. Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol. 2013;44:183-93. PubMed PMID: 22362575.
31. Gan EY, Chong WS, Tey HL. Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents. BioDrugs: Clin Immunother Biopharm Gene Ther. 2013;27:359-73. PubMed PMID: 23580094.
32. McInnes IB, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs JD, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-tosevere psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Annals of the rheumatic diseases. 2013 Jan 29. PubMed PMID: 23361084.